Advanced glycation end-products induced VEGF production and inflammatory responses in human synoviocytes via RAGE-NF-κB pathway activation

Journal of Orthopaedic Research

Volumn 34, Issue 5, 2016, Pages 791-800

  Chen, Ying Ju ^a   Chan, Ding Cheng ^b   Chiang, Chih Kang ^b   Wang, Ching Chia ^a   Yang, Ting Hua ^b   Lan, Kuo Cheng ^c   Chao, Sung Chuan ^b   Tsai, Keh Sung ^a   Yang, Rong Sen ^a   Liu, Shing Hwa ^a,d  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

advanced glycation end products (AGEs); osteoarthritis; receptor for AGEs (RAGE); synoviocytes; vascular endothelial growth factor

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; CYCLOOXYGENASE 2; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; METALLOPROTEINASE; PROSTAGLANDIN E2; TRANSCRIPTION FACTOR RELA; VASCULOTROPIN; COLLAGENASE 3; I KAPPA B; IL6 PROTEIN, HUMAN; MMP13 PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ARTICLE; DISEASE SEVERITY; ENZYME PHOSPHORYLATION; INFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SYNOVIOCYTE; CELL CULTURE; HUMAN; METABOLISM;

CELLS, CULTURED; CYCLOOXYGENASE 2; DINOPROSTONE; GLYCATION END PRODUCTS, ADVANCED; HUMANS; I-KAPPA B PROTEINS; INFLAMMATION; INTERLEUKIN-6; MATRIX METALLOPROTEINASE 13; NF-KAPPA B; RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS; SIGNAL TRANSDUCTION; SYNOVIOCYTES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84948799299     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.23083     Document Type: Article

References (50)

1. Bijlsma JW, Berenbaum F, Lafeber FP,. 2011. Osteoarthritis: an update with relevance for clinical practice. Lancet 377: 2115-2126.
2. Samuels J, Krasnokutsky S, Abramson SB,. 2008. Osteoarthritis: a tale of three tissues. Bull NYU Hosp Jt Dis 66: 244-250.
3. Smith RL,. 1999. Degradative enzymes in osteoarthritis. Front Biosci 4: 704-712.
4. Nagase H, Woessner JF Jr., 1999. Matrix metalloproteinases. J Biol Chem 274: 21491-21494.
5. Pelletier J-P, Martel-Pelletier J, Howell DS, et al., 1983. Collagenase and collagenolytic activity in human osteoarthritic cartilage. Arthritis Rheum 26: 63-68.
6. Billinghurst RC, Dahlberg L, Ionescu M, et al., 1997. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 99: 1534-1545.
7. Lakey RL, Cawston TE,. 2009. Sulfasalazine blocks the release of proteoglycan and collagen from cytokine stimulated cartilage and down-regulates metalloproteinases. Rheumatology 48: 1208-1212.
8. Blagojevic M, Jinks C, Jeffery A, et al., 2010. Risk factors for onset of osteoarthritis of the knee in older adults: a systematic review and meta-analysis. Osteoarthritis Cartilage 18: 24-33.
9. Felson DT, Zhang Y,. 1998. An update on the epidemiology of knee and hiposteoarthritis with a view to prevention. Arthritis Rheum 41: 1343-1355.
10. Piperi C, Adamopoulos C, Dalagiorgou G, et al., 2012. Crosstalk between advanced glycation and endoplasmic reticulum stress: emerging therapeutic targeting for metabolic diseases. J Clin Endocrinol Metab 97: 2231-2242.
11. Verzijl N, DeGroot J, Oldehinkel E, et al., 2000. Age-related accumulation of Maillard reaction products in human articular cartilage collagen. Biochem J 350: 381-387.
12. DeGroot J,. 2004. The AGE of the matrix: chemistry, consequence and cure. Curr Opin Pharmacol 4: 301-305.
13. Verzijl N, DeGroot J, Thorpe SR, et al., 2000. Effect of collagen turnover on the accumulation of advanced glycation end products. J Biol Chem 275: 39027-39031.
14. Verzijl N, DeGroot J, Ben ZC, et al., 2002. Crosslinking by advanced glycation end products increases the stiffness of the collagen network in human articular cartilage: a possible mechanism through which age is a risk factor for osteoarthritis. Arthritis Rheum 46: 114-123.
15. Barland P, Novikoff AB, Hamerman D,. 1962. Electron microscopy of the human synovial membrane. J Cell Biol 14: 207-220.
16. Schneider N, Mouithys-Mickalad AL, Lejeune JP, et al., 2005. Synoviocytes, not chondrocytes, release free radicalsafter cycles of anoxia/re-oxygenation. Biochem Biophys Res Commun 334: 669-673.
17. Bondeson J, Wainwright SD, Lauder S, et al., 2006. The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. Arthritis Res Ther 8: R187.
18. Hofmann MA, Drury S, Hudson BI, et al., 2002. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 3: 123-135.
19. Drinda S, Franke S, Canet CC, et al., 2002. Identification of the advanced glycation end products N-carboxymethyllysine in the synovial tissue of patients with rheumatoid arthritis. Ann Rheum Dis 61: 488-492.
20. Drinda S, Franke S, Ruster M, et al., 2005. Identification of the receptor for advanced glycation end products in synovial tissue of patients with rheumatoid arthritis. Rheumatol Int 25: 411-413.
21. Franke S, Sommer M, Ruster C, et al., 2009. Advanced glycation end products induce cell cycle arrest and proinflammatory changes in osteoarthritic fibroblast-like synovial cells. Arthritis Res Ther 11: R136.
22. Steenvoorden MM, Toes RE, Ronday HK, et al., 2007. RAGE activation induces invasiveness of RA fibroblast-like synoviocytes in vitro. Clin Exp Rheumatol 25: 740-742.
23. Rasheed Z, Akhtar N, Haqqi TM,. 2011. Advanced glycation end products induce the expression of interleukin-6 and interleukin-8 by receptor for advanced glycation end product-mediated activation of mitogen-activated protein kinases and nuclear factor-kB in human osteoarthritis chondrocytes. Rheumatology 50: 838-851.
24. Chen YJ, Sheu ML, Tsai KS, et al., 2013. Advanced glycation end products induce peroxisome proliferator-activated receptor γ down-regulation-related inflammatory signals in human chondrocytes via Toll-like receptor-4 and receptor for advanced glycation end products. PLoS ONE 8: e66611.
25. Pufe T, Lemke A, Kurz B, et al., 2004. Mechanical overload induces VEGF in cartilage discs via hypoxia-inducible factor. Am J Pathol 164: 185-192.
26. Neufeld G, Cohen T, Gengrinovitch S, et al., 1999. Vascular endothelial growth factor (VEGF) and its receptors. EMBO J 13: 9-22.
27. Lamoreaux WJ, Fitzgerald ME, Reiner A, et al., 1998. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res 55: 29-42.
28. Unemori EN, Ferrara N, Bauer EA, et al., 1992. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol. 153: 557-562.
29. Zucker S, Mirza H, Conner CE, et al., 1998. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int J Cancer 75: 780-786.
30. Enomoto H, Inoki I, Komiya K, et al., 2003. Vascular endothelial growth factor isoforms and their receptors are expressed in human osteoarthritic cartilage. Am J Pathol 162: 171-181.
31. Gillery P,. 2006. Oxidative stress and protein glycation in diabetes mellitus. Ann Biol Clin (Paris) 64: 309-314.
32. Steenvoorden MM, Huizinga TW, Verzijl N, et al., 2006. Activation of receptor for advanced glycation end products in osteoarthritis leads to increased stimulation of chondrocytes and synoviocytes. Arthritis Rheum 54: 253-256.
33. McCance DR, Dyer DG, Dunn JA, et al., 1993. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 91: 2470-2478.
34. DeGroot J, Verzijl N, Wenting-van Wijk MJ, et al., 2004. Accumulation of advanced glycation end products as a molecular mechanism for aging as a risk factor in osteoarthritis. Arthritis Rheum 50: 1207-1215.
35. Nah SS, Choi IY, Lee CK, et al., 2008. Effects of advanced glycation end products on the expression of COX-2, PGE2 and NO in human osteoarthritic chondrocytes. Rheumatology 47: 425-431.
36. Huang C, Lai K, Hung L, et al., 2011. Advanced glycation end products cause collagen II reduction by activating Janus kinase/signal transducer and activator of transcription 3 pathway in porcine chondrocytes. Rheumatology 50: 1379-1389.
37. Scanzello CR, Goldring SR,. 2012. The role of synovitis in osteoarthritis pathogenesis. Bone 51: 249-257.
38. Senolt L, Braun M, Olejárová M, et al., 2005. Increased pentosidine, an advanced glycation end product, in serum and synovial fluid from patients with knee osteoarthritis and its relation with cartilage oligomeric matrix protein. Ann Rheum Dis 64: 886-890.
39. Hou FF, Jiang JP, Guo JQ, et al., 2002. Receptor for advanced glycation end products on human synovial fibroblasts: role in the pathogenesis of dialysis-related amyloidosis. J Am Soc Nephrol 13: 1296-1306.
40. Hou CH, Fong YC, Tang CH,. 2011. HMGB-1 induces IL-6 production in human synovial fibroblasts through c-Src, Akt and NF-κB pathways. J Cell Physiol 226: 2006-2015.
41. Akira S, Taga T, Kishimoto T,. 1993. Interleukin 6 in biology and medicine. Adv Immunol 54: 1-78.
42. Lewis EJ, Bishop J, Bottomley KM, et al., 1997. Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. Br J Pharmacol 121: 540-546.
43. Pages G, Pouyssegur J,. 2005. Transcriptional regulation of the vascular endothelial growth factor gene-a concert of activating factors. Cardiovasc Res 65: 564-573.
44. Oeckinghaus A, Ghosh S,. 2009. The NF-kB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol 1: a000034.
45. Hou CH, Tang CH, Hsu CJ, et al., 2013. CCN4 induces IL-6 production through avb5receptor, PI3K, Akt, and NF-kB singling pathway in human synovial fibroblasts. Arthritis Res Ther 15: R19.
46. Krasnokutsky S, Attur M, Palmer G, et al., 2008. Current concepts in the pathogenesis of osteoarthritis. Osteoarthritis Cartilage 16: S1-S3.
47. Scanzello CR, Goldring SR,. 2012. The role of synovitis in osteoarthritis pathogenesis. Bone 51: 249-257.
48. Roman-Blas JA, Jimenez SA,. 2006. NF-κB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 14: 839-848.
49. Tsai CH, Chiang YC, Chen HT, et al., 2013. High glucose induces vascular endothelial growth factor production in human synovial fibroblasts through reactive oxygen species generation. Biochim Biophys Acta 1830: 2649-2658.
50. Berra E, Pagès G, Pouysségur J., 2000. MAP kinases and hypoxia in the control of VEGF expression. Cancer Metastasis Rev 19: 139-145.